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Abstract
Background: A specialist depression service (SDS) offering collaborative pharmacological and cognitive behaviour
therapy treatment for persistent depressive disorder showed effectiveness against depression symptoms versus
usual community based multidisciplinary care in a randomised controlled trial (RCT) in specialist mental health
services in England. However, there is uncertainty concerning how specialist depression services effect such change.
The current study aimed to evaluate the factors which may explain the greater effectiveness of SDS compared to
Treatment as Usual (TAU) by exploring the experience of the RCT participants.
Methods: Qualitative audiotaped and transcribed semi-structured interviews were conducted 12–18 months after
baseline with 21 service users (12 SDS, 9 TAU arms) drawn from all three sites. Inductive thematic analysis using a
grounded approach contrasted the experiences of SDS with TAU participants.
Results: Four themes emerged in relation to service user experience: 1. Specific treatment components of the SDS:
which included sub-themes of the management of medication change, explaining and developing treatment
strategies, setting realistic expectations, and person-centred and holistic approach; 2. Individual qualities of SDS
clinicians; 3. Collaborative team context in SDS: which included sub-themes of communication between healthcare
professionals, and continuity of team members; 4. Accessibility to SDS: which included sub-themes of flexibility of
locations, frequent consultation as reinforcement, gradual pace of treatment, and challenges of returning to usual care.
Conclusions: The study uncovered important mechanisms and contextual factors in the SDS that service users
experience as different from TAU, and which may explain the greater effectiveness of the SDS: the technical expertise of
the healthcare professionals, personal qualities of clinicians, teamwork, gradual pace of care, accessibility and managing
service transitions. Usual care in other specialist mental health services may share many of the features from the SDS.
Trial registration: “Trial of the Clinical and Cost Effectiveness of a Specialist Expert Mood Disorder Team for Refractory
Unipolar Depressive Disorder” was registered in www.ClinicalTrials.gov (NCT01047124) on 12–01-2010 and the ISRCTN
registry was registered in www.isrctn.com (ISRCTN10963342) on 25–11-2015 (retrospectively registered).
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Background
Major depressive disorder is experienced by up to 15%
of people in high income countries at least once in their
lifetime [1]. It has been identified as the second leading
cause of years lived with disability in the world [2]. Fur-
thermore, recurrence of major depressive disorder is
high, rising from a rate of 60% recurrence 5 years after
an episode of depression to 85% after 15 years [3].
Combined pharmacotherapy and psychological treat-
ments delivered by specialist multi-professional teams
are widely recommended [4]. This collaborative care ap-
proach is characterised by joint assessments by psychia-
trists and psychological therapists, and the development
of structured management plans according to protocols
for both psychotherapy and pharmacology based on
NICE Guidelines for depression (2009) [5]. However,
only a small number of randomised controlled trials
(RCTs) have examined the effectiveness of such a collab-
orative treatment service for persistent, chronic or treat-
ment resistant moderate-to-severe depressive disorder
(e.g. [6]). In our primary study, a large scale RCT of a
Specialist Depression Service (SDS) providing pharma-
cotherapy and psychological treatment from a collabora-
tive specialist team [7] showed a significant reduction in
depression symptoms after 18 months [8]. However,
there is uncertainty about the factors which may con-
tribute to these improved outcomes for people experien-
cing severe and recurring depression [9] and service
users’ experience of these.
There is little research evidence to date examining the
factors that influence the effectiveness of collaborative
care models for depression. The NICE 2017 draft guide-
lines for depression [10] includes an analysis showing
that improved outcomes from collaborative care for de-
pression were mediated by having stepped care where
another treatment is used if the first is not responsive,
decision-support between the psychiatrist and psycho-
therapist, and having a medication algorithm. Longer ill-
ness duration is a robust predictor of poor outcome in
antidepressant-placebo drug trials and combinations of
psychotherapy and antidepressant treatment studies
[11–14]. Length of therapeutic intervention appears to
be an important factor for longer-term remission from
depression symptoms [15], and one trial has found that
more than 16 sessions of either CBT or psychodynamic
supportive therapy were needed to achieve remission
[16]. In psychotherapy research, therapeutic alliance
when rated by the patient and adherence by the therap-
ist to the treatment manual have been found to be a
moderator of outcomes [17]. Together, these findings
suggest the future design of services for people with re-
current depression should aim to foster a longer-term
and collaborative approach to building therapeutic
relationships.
Qualitative methods have been shown to provide a
useful approach to understanding participants’ percep-
tions and experiences of an intervention and to identify
the active ingredients of complex and multi-faceted
mental health services [18–21]. Romakkaniemi and Kil-
pelainen [22] analysed the experiences of two service
users with depression through their written blogs and
found four themes: a confident working relationship,
time and hiatus for finding one’s own authenticity, suc-
cessful timing of interventions and a holistic view of life.
However, this study did not examine the experience of a
single service, rather their experience of multiple ser-
vices over time.
The aims of this qualitative study into service user ex-
periences were to:
 Obtain service user views on their experience of
either the SDS or Treatment as Usual (TAU) as part
of a large RCT
 Identify the features of the SDS intervention that
were experienced as beneficial
 Compare the experience of those in different arms
of the study
Methods
SDS trial design
The SDS treatment groups received a collaborative care
approach between patient, psychiatrist and cognitive be-
haviour therapist, and, where clinically indicated, contact
with the patient’s General Practitioner (GP) and commu-
nity mental health teams, voluntary sector organisations,
family and friends and employers. The SDS collaborative
approach began with a joint assessment between service
user, psychiatrist and CBT therapist. Follow up sessions
using the same format were conducted at 3,6,9 and
12 months. The intervention was characterised by opti-
mised pharmacotherapy (meeting individually with the
psychiatrist initially fortnightly tapering to monthly and
three monthly once optimised). Alongside this was
weekly Beckian CBT with an option for Mindful-
ness Based Cognitive Therapy as a relapse prevention
strategy. From month 10 there was a gradual transition
to usual care with either primary care or secondary care
community teams after 13 months (range 12–15). The
SDS groups also took an active social inclusion and re-
covery stance [23] and had links with local social inclu-
sion initiatives (i.e. vocational, educational and back to
work and self-help support networks). The services
aimed to deliver a collaborative and integrated psycho-
biosocial model of treatment [24] in which equal import-
ance is given to medication and psychosocial
interventions as treatments of potential benefit, and the
initial treatment rationale presented explicitly articulated
the reasons for using each in combination. All
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treatments were National Institute for Health and Care
Excellence (NICE) –recommended [4] and delivered by
staff with a high level of training and clinical expertise in
treating depression.
TAU was directed by a consultant psychiatrist and
consisted of pharmacotherapy, sometimes augmented by
psychological interventions but without co-ordination or
joint reviews and assessments between healthcare pro-
fessionals [7, 8].
Study sites
The Specialised Depression Service was implemented in
the three free to the public specialist mental health ser-
vices operated by the National Health Service in England
in Nottinghamshire, Cambridgeshire and Derbyshire.
Participants in the RCT
The RCT recruited 187 participants with moderate to se-
vere depression from the three sites as follows: Nottingham
(137), Derby (21) and Cambridge (29):. 93 were assigned to
SDS and 94 to TAU. Figure 1 shows the flow of participants
through the trial. Inclusion criteria for the RCT were a pri-
mary diagnosis of major depressive disorder; continuing
contact with specialist mental health services after 6
months, score 16 or above on the 17-item Hamilton Rating
Scale for Depression (HRSD) [25] and 60 or below on the
Global Assessment of Functioning (GAF) [26]. Exclusion
criteria were such that patients were excluded if they were
in receipt of emergency care for suicide risk, homicide risk
or severe neglect, but patients were not excluded because
of such risks provided these risks were adequately con-
tained in their current care setting and the primary medical
responsibility for care was with the referral team. They were
also excluded if they were pregnant, did not speak fluent
English or had depression secondary to another primary
psychiatric or organic condition. Patients were recruited
from the existing caseloads of secondary care mental health
teams at each site. Table 1 shows sociodemographic and
clinical characteristics of the sample in the RCT at baseline,
primary outcome results from baseline to 18 months, and
contacts with psychiatrists and psychotherapists over
18 months (see [8] for more details). The cohort recruited
was substantially more depressed, functionally impaired,
and had both depression symptoms and treatment for lon-
ger than required for entry to the study. As such, they rep-
resent a group that presents challenges for treatment and
management and that frequently have poor outcomes.
Participants in the qualitative study
Semi-structured interviews were conducted by MB, an ex-
perienced qualitative interviewer, with a maximum vari-
ance sample of service users from both the SDS (n = 12)
and TAU arms (n = 9) at 12–18 months after baseline at
the end of SDS treatment (total sample n = 21) (Table 2).
The criteria for achieving the maximum variance sample
were: study site, dropping out of follow-up, dropping out
of treatment, completing treatment and completing of fol-
low up, gender, age bands (18–30, 31–45, 46–55, over
55 years old at baseline), marital status, living on own or
someone else, having a children or not, completed educa-
tion at 18 or not, in work or not, time since first diagnosis,
current medical comorbidity or not, other current mental
comorbidity or not, moderately severe or severe at base-
line, whether or not has psychotherapist at baseline,
whether or not has care coordinator at baseline. Twenty
one participants were selected for interview as this was
the number required to check off all of these criteria. A
topic guide was used to structure the interviews (Table 3).
All interviews were audiotaped.
Analysis
All interviews were transcribed by MB and NVivo 10
was used to manage the transcripts and data coding. In-
ductive thematic analysis using a grounded approach
was adopted [27]. Initially, all transcripts were read care-
fully to identify sections of text relevant to service users’
experience of SDS or control arm. LT analysed the tran-
scripts for each interview separately and generated initial
codes from the relevant data using open coding. Emer-
ging codes were tested and modified by constant com-
parison. Coded data were then collated into broader
themes and sub-themes, which were reviewed with other
members of the research team (RM, CKH, AG), before
the definition and labelling of each theme were agreed
upon. Quotations were selected to illustrate each theme.
Results
Four main themes emerged from the data that related to
service user experience: specific treatment components
of the SDS; the individual qualities of clinicians; the col-
laborative team approach; and the accessibility of the
SDS treatments.
Treatment components of the SDS
Participants were able to identify specific elements of
the treatment that they had received from clinicians de-
livering the SDS that had been particularly effective or
different from their experiences of previous treatment.
The sub-themes that emerged described those elements
of the SDS treatments that participants had valued.
Management of Medication Changes
Participants who had received the SDS commented on
the efficiency and clarity of any medication changes that
were made during their treatment. Any changes to medi-
cation were discussed, and different options explained,
so that the service user felt informed and engaged with
the decision-making.
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“not only did she make suggestions but she explained
kind of a route through so it is like ‘well we can try
this, but if this doesn’t work then we have got other
options and …. which way do you think would be best
to go first?’ and so you kind of knew more where you
were” SU2 (SDS).
Furthermore, any changes made to medication
through the SDS were very rapidly implemented, and
avoided delays that had been commonly experienced in
previous treatments.
“if they said we want to change it, you would change it
then it would happen that day” SU1 (SDS).
Explaining and developing treatment strategies
Participants described the positive experience of clini-
cians explaining aspects of their depression, medication
and therapies to them as part of their treatment within
the SDS. They gained benefits from feeling more in-
formed about and developing a more objective view of
their condition.
Fig. 1 Flow of participants through the trial
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“there is stuff I don’t know and stuff I don’t
understand and he will explain it to me, he will get a
flipchart out right I will show you. This is how your
brain works this is what that does if you feel like that,
it triggers that and it’s wonderful, and I like just being
able to understand it makes me feel a lot better….. he
helps me to have some objective view of myself” SU21
(SDS).
This understanding supported the participants to use
the cognitive behavioural strategies more effectively after
the trial had ended.
“I feel I have been struggling a bit since I finished but...
but then I worked out my own sheets, where I chart
my mood every day …. So as soon as [my mood] starts
to drop I try and be on it and do something about it.”
SU25 (SDS).
In comparison, those in the TAU arm described a cycle
of routine appointments that did not engage them in
their treatment and gave them no optimism for the
future.
“my current a doctor once every 3 months…. Once
every 3 months. … That is no help. It is just keeping
the paperwork up to speed isn’t it” SU12 (TAU).
Setting realistic expectations
Participants described gaining a more realistic expect-
ation of what their recovery might look like through
their interactions with clinicians from the SDS. This
largely concerned adjusting their assumptions that re-
covery meant being free from symptoms and no longer
taking medication. Participants receiving the SDS de-
scribed how they had accepted that periods of depres-
sion may still occur and that they may need to stay on
some form of medication for the longer term.
“I always assumed that I would get better and that
would mean not being on tablets. … I think I spent
Table 1 Baseline characteristics of the main RCT sample, outcomes and care received
TAU SDS
(n = 94) (n = 93)
Age, mean (sd,) 46 (11.3) 47 (11.6)
Gender, female, n (%) 60 (64) 54 (58)
Employment status, n (%) [n = 91] [n = 90]
Full-time employment 22 (26) 17 (19)
Other employmenta 11 (12) 10 (11)
Retired 10 (11) 16 (18)
Unemployed 37 (41) 36 (40)
Married or co-habiting, n (%) 50 (53) 42 (45)
Years since first diagnosis of depression mean (sd) 16.9 (11.6) 16.5 (11.1)
Depressed > 1 year, n (%) 82 (87) 80 (86)
HDRS17, baseline mean (sd) 23.2 (5.8) 22.0 (4.5)
6 month mean (95% CI) drop −3.76(−5.45, −2.07) −4.77(−6.32, − 3.22)
12 month mean (95% CI) drop −4.99(− 7.04, − 2.94) −7.44(− 8.98, − 5.90)
18 month mean (95% CI drop)* −6.00(− 8.13, − 3.87) −8.96(− 10.64, − 7.28)
GAF, baseline mean (sd) 47.7 (9.4) 49.3 (6.8)
6 month mean (95% CI) gain 4.61(1.51, 7.70) 5.93(3.08, 8.79)
12 month mean (95% CI) gain 5.14(1.99, 8.28) 9.26(6.31, 12.21)
18 month mean (95% CI) gain** 5.60(2.17, 9.03) 9.42(6.53, 12.31)
Median (range) number of appointments
With psychiatrist, 0–18 months 8 (0–45) 17 (0–92)
With psychotherapist, 0–18 month 4.5 (0–49) 18 (0–67)
HDRS17 17 item Hamilton Depression Rating Scale
GAF Global Assessment of Function
*SDS significantly more effective than TAU p = 0.015
**SDS non-significantly more effective than TAU, p = 0.113
SDS = Specialist Depression Service; TAU = treatment as usual
aOther employment: part-time, sheltered and voluntary employment and higher education
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time with [clinician], really, he’s got me used to the
idea that I will probably be on something to keep me
level in the long term. I think I’ve just about got used
to that idea now. Whereas before, it was just
completely out of the question.” SU15 (SDS).
A person-centred approach
Clinicians delivering the SDS provided an individualised
and person-centred approach to service users. This was
characterised by asking service users about their needs
and allowing them to take the lead in setting the agenda
and focus for the sessions.
“I am asked what I want to talk about at the beginning
of every session, what do I think will help me, what do I
want, what is making me unhappy, you know what is
working for me so, …. it is different, it’s very different
and a little disconcerting at first” SU21 (SDS).
In contrast, participants in the TAU arm had not expe-
rienced this individualised, tailored approach and
expressed frustration that their treatment did not ad-
dress their individual needs.
“we are not all the same, yes we might be suffering
from the same symptoms but we are all different
people, and we all need handling in different ways”
SU30 (TAU).
A holistic approach
Related to this focus on the individual person, the ser-
vice users also experienced a more holistic approach
from clinicians in the SDS. Participants found that the
clinicians were interested in their overall well-being and
quality of life, including physical health, social activity
and employment, rather than just their mental health.
Clinicians provided practical help in accessing physio-
therapy, attending social groups and gaining benefits ad-
vice. This was in contrast to participants’ experience of
previous treatments which had solely focused on their
mental health. Service users also reflected that they had
learnt how inter-related their mental health was with
other aspects of their health and life.
Table 2 Demographic and clinical characteristics of the qualitative sample
UIC Site Arm of the Study Completed Treatment (6 m+) Follow Ups Completed (up to 24 months +) HRSD baseline HRSD 18 months
SU15 N SDS Yes Yes 21 23
SU1 N SDS Yes Yes 20 11
SU24 N SDS Yes Yes 24 1
SU27 N SDS Yes Yes 24 6
SU7 N SDS Yes Yes 27 10
SU25 N SDS Yes Yes 17 5
SU11 N TAU N/A Yes 16 18
SU12 N TAU N/A Yes 25 24
SU17 N TAU N/A Yes 16 6
SU23 N TAU N/A Yes 27 19
SU2 C SDS Yes Yes 25 12
SU19 C SDS Yes Yes 20 18
SU16 C SDS Yes Yes 22 3
SU29 C TAU N/A Yes 26 22
SU30 C TAU N/A Yes 19 14
SU21 D SDS Yes Yes 16 8
SU4 D SDS Yes Up to 12 m 19 DNC
SU8 D SDS Yes Yes 24 25
SU6 D TAU N/A Yes 18 29
SU18 D TAU N/A Up to 18 m 19 18
SU26 D TAU N/A Up to 18 m 18 20
N Nottingham, C Cambridge, D Derby; SDS Specialist Depression Service, TAU treatment as usual; HDRS 17-item Hamilton Depression Rating Scale, DNC Did
Not Complete
Completed Treatment: Completed up to 6 m or more
Time of interview: Interview was conducted after this time point
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“The fact that they looked at all of my health sort of
mental and physical because the two are intertwined I
mean they can’t be separated ... and I have understood
more clearly that that is the case since I have been on
the study. That was something that was never looked
at before, so all that the people before were concerned
about was the mental health side of things, and I
wasn’t even asked about any of the physical health or
anything like that.” SU2 (SDS).
Individual qualities of SDS clinicians
In addition to specific elements of the treatment that
they had received through the SDS, participants de-
scribed the personal qualities and behaviours of individ-
ual clinicians as being important aspects of their
experience of the service. A range of qualities were de-
scribed by participants including: being calm and re-
laxed, empathetic, non-judgemental, re-assuring,
positive, and having the ability to get people to open up.
This last quality was particularly highlighted by partici-
pants and contrasted with their previous experience of
treatments. Participants described developing a connec-
tion with the clinicians, allowing them to open up and
trust their clinicians which they believed had helped
with their engagement with the treatment.
“I find this a lot better, … I have been able to open up
more... probably share more things than I ever have
shared any before ... I don’t know whether it’s because
of this particular [clinician] the way she is, has...
worked with me and allowed me to open up …. I
found I have been able to talk openly and honestly
with her.” SU8 (SDS).
The importance of making a positive and trusting con-
nection with a clinician was highlighted by one partici-
pant from the TAU arm of the study who had not
experienced a positive working relationship.
“I think it was of limited use because I didn’t get on
with the therapist…. she wasn’t somebody I could
really open up to, or talk to, I guess you know I didn’t
trust her …. just not somebody I felt comfortable
[with]… because I didn’t feel that she got me or
understood me or whatever so, you know that puts a
barrier between you kind of opening up.” SU17 (TAU).
In contrast, a few participants in the TAU arm did ex-
perience a more positive relationship with their clini-
cians, and found this beneficial to their treatment.
“she was the only one really that I think understood... I
really was grateful because the understanding has
never been there before if you know what I mean”
SU23 (TAU).
A collaborative team context
Service users who had experienced the SDS were able to
articulate the differences in their treatment due to the
collaborative team approach. These focused on two main
aspects: improved communication between healthcare
professionals, and continuity amongst team members.
Communication between healthcare professionals
It was obvious to service users that the clinicians in-
volved in the treatment had been sharing information
and discussing aspects of their treatment. The know-
ledge that the clinical team were all talking to each other
about the service users’ treatment was identified as sig-
nificantly different from previous experiences, and gave
service users confidence in the approach to their treat-
ment, and that all clinicians involved were fully informed
about other aspects of their treatment.
“They seem to work so well as a team, … I can speak
to someone like [therapist] and I will see [psychiatrist]
Table 3 Interview Topic Guide
1. What can you tell me about how you became involved in this
research?
• Who told you about it
• How they told you
• Why you wanted to be part of this research
2. Can you tell me why this research is needed?
• What does this service offer now?
• Do you know what the desired outcome of the research is?
3. Do you have views on how you would like the service here to
change?
4. Do you know who is involved in this research, which doctors, nurses
or other people?
5. What are you hoping to get from your involvement with the
research/service?
6. In addition to the services you receive here, do you take any other
steps to relieve your symptoms?
7. Could involvement in this research lead you to do anything
different?
8. Have you seen changes in the service since you first became a
service user?
9. Do you know what has helped to make change happen? (give
examples)
10. Or got in the way of change happening? (give examples)
11. Looking at the research and the efforts to improve the service, are
there any things you would have liked to see done differently?
12. Is there anything else that you would like to tell me?
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two or three weeks later and she will speak to me
about what [therapist] said, so I know it gets passed
on, I know they are all talking to each other.” SU16
(SDS).
In contrast, participants in the TAU arm were not
confident about the exchange of information between
different clinicians that may be involved in their care.
“I have only got my psychiatrist really to talk to, and
he was showing me ways by getting in touch with a
separate organisation to, but then they won’t be
talking to him to kind of you know [about me]” SU29
(TAU).
Continuity of team members
Having clinical team members that were consistent and
unchanged throughout the study was also experienced
as something quite different from previous treatments
and the TAU arm. This continuity was described as be-
ing beneficial to developing trust and confidence in the
clinicians, which in turn benefitted their engagement
with treatment.
“I think the most important factors are the
continuation of the same people, and the distinction
between their different roles… It give me confidence in
them.” SU2 (SDS).
In contrast, the TAU participants described the impact
of seeing different clinicians during treatments, both
during the study and through prior experience. Many
participants from both arms of the study described their
previous experiences of constantly changing psychiatrists
and the frustrations of having to retell their experiences
from the beginning on multiple occasions. In addition,
the uncertainty and concern that was experienced due
to changing clinicians was felt to be particularly dam-
aging for people with depression.
“change for me isn’t a good thing because I have to
reset all my, or rearrange all my parameters … what
makes me feel safe and stuff, so seeing somebody new
… in general was a problem” SU30 (TAU).
Accessibility to SDS
Participants who had experienced the SDS described the
benefits of an easily and frequently accessed service.
Access outside appointment times
Participants felt reassured that they could access the ser-
vice to make additional appointments to those already
made if they needed to. In reality, they rarely made add-
itional appointments but the knowledge that this was
available appears sufficient to convey some benefit to the
service users.
“knowing that if things were bad, I could phone her up
and get an urgent appointment with her, was more
valuable than actually doing it to be honest. … I can’t
stress enough how important that is, really important.”
SU24 (SDS).
This contrasted sharply with the experience of partici-
pants in the TAU arm who described the challenges of
getting earlier appointments or talking to someone be-
tween appointments, and negative impact of having a
service unresponsive to the needs of service users at crit-
ical times.
“It is like trying to get into Fort Knox, to try and maybe
get an earlier appointment. I have rung the secretary
and said ‘I really could do with...’ By the time I get one
it’s my appointment time anyway.” SU8 (TAU).
Flexible locations
A number of participants described the benefits of being
able to have consultations take place in their homes. This
flexibility provided both reassurance and a sense of safety
to the service users who had requested this. But one par-
ticipant also thought it gave the clinician some additional
insights into the service user’s state of mental health.
“It’s been really, really good that she has come to me
most of the time at home, because that’s, that is really
significant actually…. I would think it helps [the
clinician]... because she can see at any given time how
well I am kind of looking after things,... she has definitely
seen it in various states, but also just for her to know the
environment in which I am in.” SU2 (SDS).
Frequent consultations
Participants reported that the frequent and ongoing con-
sultations in the SDS was of benefit to them. They felt
that their treatment was very proactive with more time
invested by clinicians. This was particularly important in
relation to their application of CBT techniques and skills
learnt in consultations, and the need for reminders and
reinforcement of the techniques learnt.
“There were a couple of times where I was on holiday
or [the clinician] was on holiday and you know it was
two weeks [between appointments] and it just gives
you that much time to slip back a bit. Whereas if you
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have got a week, you can keep it in your head and you
can work on whatever the ideas that you are working
on. And then remember it and feedback, quite
effectively.” SU24 (SDS).
By the end of the trial some service users reported a
decline when the frequent consultations had stopped,
again pointing to the benefits of having regular re-
minders of the CBT techniques.
“I’m almost a year out of the project now and I can
feel I’m slowly slipping back down again. But there’s
more regular times on the [trial] and that year
afterwards. It did away with all of that and I did feel
there was some hope.” SU15 (SDS).
In contrast, service users in the TAU described how
the infrequent sessions and time-limited nature of the
service prevented them making progress, largely through
the additional time taken to build an effective thera-
peutic relationship.
“you are talking about 4 or 5 almost 6 sessions to
really start trusting somebody because each time
they chip away at you and you, you let a bit out
and you are still guarded and yes, so you are
talking what 3 months say, you know before you are
really opening up completely. And obviously you are
not going to get anywhere unless you open up to
these people, you are not going to get any better”
SU29 (TAU).
Gradual pace of treatment
Participants receiving the SDS frequently reported that
the 12 month duration of treatment allowed a better
pace to be established. Participants didn’t feel rushed
which in turn led to better engagement, and more estab-
lished recovery allowing service users to recover better
from periods of depression.
“you can do it so rigorously when it’s once a week for a
whole year it’s really, it just becomes part of like the
foundation, the missing bits of foundation. And then
it’s I don’t know it’s just there for you to fall back on”
SU25 SDS.
Having time to get service users to the point at which
they can start to fully engage with the treatment and the
CBT techniques was seen as one of the benefits of a lon-
ger treatment cycle. A participants receiving the Treat-
ment as Usual arm described this in relation to time-
limited therapy sessions.
“you get your 20 sessions or your 10 sessions or
whatever, [but] what if you are in a state where it
takes 6 or 7 sessions to get to the point where you can
intellectually connect with the process and really do it
properly…. And it doesn’t have time to take effect and
yes it gets you out of the, being in a pit of misery but it
doesn’t stop you going back into it the next time
something horrendous happens.” SU24 TAU.
Challenge of returning to TAU
Some participants who had received the SDS found the
transition back to the usual frequency of appointments a
difficult process. Moving from the enhanced accessibility
and frequency of their treatment in the SDS arm of the
trial to the more infrequent sessions experienced in
usual care also meant that they were subject to the diffi-
culties of cancelled appointments and changing
clinicians.
“Well I mean that was appalling really in the sense
that you know you have been seeing somebody
regularly and trustworthingly…, you then got referred
back to your GP basically and the mental health
services ….[and that appointment was cancelled] so it
was 4, nearly 4 or 5 months or something in that order
before I next saw a... mental health professional” SU1
(SDS).
Participants also missed the frequent contact with cli-
nicians and described how they need to be more pro-
active in their own use of the CBT techniques.
“CBT teaches you to almost not have to go tell people
things doesn’t it, it’s like you are your own sort of
mentor aren’t you but, I think there is also part of me
needs to just talk things over with somebody from time
to time I think… But, I just lost my objectivity a bit, …
So maybe if I just had a chat with someone at 3
months perhaps” SU25 (SDS).
Further difficulties were experienced by participants
due to lack of clear communication about the end of the
trial and the transition back to usual care.
“I didn’t realise my last session with him was my last
session… And he came in and said, last one. And I
just burst into tears. But that was, I was scared, I
thought I wasn’t going to have that one last throw of
the dice, if you like.” SU15 (SDS).
However, the longer-term impact of the SDS was re-
ported by some of the participants.
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But there’s more regular times on the [trial] and that
year afterwards, ….. It did away with all of that and I
did feel there was some hope. SU15 (SDS).
Discussion
The service user experience of the SDS was very posi-
tive, and participants were able to articulate elements of
the service which differed from their previous experi-
ences of treatment, and why they were beneficial to
them. Participants felt informed and engaged in the dif-
ferent elements of their treatment, both in relation to
their CBT and their medication. In the SDS, participants
felt that different options were explained and set out,
and that they had some control in setting the agenda
and having their individual needs addressed. This in-
cluded having clinicians help with other aspects of their
well-being and quality of life. Having realistic expecta-
tions about what their recovery might look like was an-
other important element of the SDS that participants
experienced. This frequently involved accepting that it
might be necessary to stay on some form of medication
and that depression symptoms may reoccur. Many of
these elements align themselves with recovery-focused
practices which aim to achieve service user defined goals
and outcomes to build a meaningful and satisfying life
that is not necessarily symptom free [28].
The personal qualities of clinicians were also
highlighted as an important element of effective treat-
ment, particularly in developing trust and encouraging
the participants to open up to the clinicians. This wasn’t
unique to the SDS arm, and similar qualities were expe-
rienced by people in the TAU arm too. This finding
highlights the benefits of developing positive working re-
lationships between service users and mental health pro-
fessionals, as has been identified in other studies [22,
29].
Aspects of the SDS collaborative team working were
also identified by participants as a beneficial feature of
their treatment that they had not experienced before.
Participants gained confidence in the knowledge that the
different clinicians involved in their treatment were
communicating effectively with each other, and informed
about the different aspects of treatment. The continuity
of team members throughout treatment further en-
hanced this communication and also supported the de-
velopment of trust between clinicians and service users,
resulting in better engagement. This was sharply con-
trasted by the participants’ previous experience of fre-
quent changes to clinicians and the negative impact this
had on their treatment.
Finally, participants described the benefits they experi-
enced from the ease and frequency of access to the SDS.
Although they rarely accessed the service outside of
their booked appointments, knowing that it was possible
to get earlier appointments reassured the service users.
Having appointments at home was also perceived to be
beneficial for a number of participants. For the CBT part
of the service, the frequency of consultations and total
length of treatment were both highlighted by partici-
pants as important factors that contrasted with their
previous experience of treatment. Frequent CBT sessions
helped participants to reinforce the techniques used, and
avoid slipping back into their usual ways of thinking.
Similarly, having a sufficient number of CBT sessions
was repeatedly stressed as being important to allow ser-
vice users to fully engage with the therapy, develop
trusting relationship with the clinician and establish the
techniques to support their prolonged recovery. The im-
portance to service users of the appropriate timing of
treatment which coincides with their own readiness has
been found in other studies [22, 30].
Although the frequency of consultations experienced
by participants in the SDS arm of the trial was perceived
by them as one of the benefits of this approach, this also
resulted in some challenges for participants once they
returned to treatment as usual when the trial had fin-
ished. The transition into usual care was difficult for
some participants to adjust to. However, there was evi-
dence from the service user interviews in the SDS arm
of changes in attitudes to treatment and coping strat-
egies indicating lasting improvement in coping with this
long-lasting and recurrent condition.
Strengths and limitations
Qualitative methods were used in this study to explore
and understand the experiences of service users with
long experience of mental health services to provide
additional insights into the mechanisms of action of the
SDS on depression symptoms versus TAU. Important as-
pects of care can be identified in a complex intervention
such as a service intervention that are difficult to cap-
ture otherwise. Most RCTs of single pharmacological or
psychological treatment interventions can explore the
process of care delivery through simple methods such as
prescribed medication and therapist competency but
care in services covers many interdependent therapeutic
approaches delivered by many different staff.
Whilst this approach enables greater depth of under-
standing of service user experience, the generalisability
of findings is limited by the nature of the sample, which
is both small and self-selecting. We did not have inter-
views with patients who dropped out early from the SDS
and may have had much more negative experiences of
such treatment. The contrast between the SDS and TAU
may be more or less marked if usual care in specialist
general mental health services has fewer or more fea-
tures in common with the SDS care outlined here.
Thomson et al. BMC Psychiatry  (2018) 18:194 Page 10 of 12
Furthermore service user experience may not reflect ac-
curately important aspects of care that is technical in na-
ture. It also did not provide insight into the non-
significant effects of SDS on functional outcomes as op-
posed to the effectiveness on depression symptoms.
Implications for practice
Service users highlighted the benefits of features of the
SDS service which were different from their previous ex-
periences of treatment and those in the control arm.
Participants positive experience of the SDS centred
around the ability to develop trusting relationships with
therapists working in a stable and collaborative team,
the frequency and accessibility of sessions and the ability
to top-up and reinforce the techniques learnt over a lon-
ger period. In addition, having a sufficiently long treat-
ment period to foster the development of trust and
positive relationships is important; service users should
not feel rushed. Participants spoke about the importance
of being able to engage with the therapists which re-
quired building up trust and connections. The need for
a gradual pace and length of treatment was reflected in
the outcome measures of the RCT where there was no
difference between the arms in any outcome measure
until 6 months and significance on the primary HDRS
outcome measure was not reached until 18 months [8].
Time-limited CBT sessions will not achieve these factors
that were widely considered to be most beneficial. These
findings concur with other studies which have demon-
strated that short-term therapies are insufficient in lead-
ing to recovery. A meta-analysis of six trials comparing
short-form psychodynamic psychotherapy with CBT for
depression found that 16–20 sessions of either therapy
was insufficient to achieve a long-term remission for pa-
tients [15]. A more recent trial [16] also found that more
than 16 sessions of either CBT or psychodynamic sup-
portive therapy were needed to achieve remission in pa-
tients attending outpatients’ clinics. Together, these
findings suggest the future design of services for people
with recurrent depression should aim to foster a longer-
term and collaborative approach to building therapeutic
relationships.
Conclusions
This study provided in-depth qualitative data about ser-
vice users’ experience of the SDS, how it differed from
their previous experiences of treatment, and why this
was beneficial to them. The findings highlight the im-
portance of some of the specific treatment components
of the SDS model, such as the careful management of
medication change, taking time to explain treatment
strategies, setting realistic expectations in relation to re-
covery, and using a person-centred and holistic ap-
proach. In addition, the individual qualities of clinicians
were highlighted as important in developing trust with
service users, which promoted better engagement with
clinicians. The collaborative nature of the SDS team pro-
vided a context of effective communication and continu-
ity within the team, which further promoted confidence
amongst service users. Finally, frequent consultations
and ease of access supported the experience of service
users, allowing them to engage in therapy at their own
pace. However, the frequency of consultations also re-
sulted in some challenges for participants once they
returned to treatment as usual when the trial had fin-
ished. The transition into usual care was difficult for
some participants to adjust to. However, there was evi-
dence from the service user interviews in the SDS arm
of changes in attitudes to treatment and coping strat-
egies indicating lasting improvement in coping with this
long-lasting and recurrent condition.
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